(Q31935290)

5 July 2017

1 reference

title

Liposomal encapsulated anthracyclines: new therapeutic horizons (English)

1 reference

5 July 2017

1

1 reference

5 July 2017

publication date

1 March 2001

1 reference

5 July 2017

published in

Current Oncology Reports

1 reference

5 July 2017

volume

3

1 reference

5 July 2017

issue

2

1 reference

5 July 2017

page(s)

156-162

1 reference

Adriamycin. A new anticancer drug with significant clinical activity

5 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-001-0016-5

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-001-0016-5

‘Daunomycin’, a New Antibiotic of the Rhodomycin Group

21 January 2018

1 reference

12 December 2020

Adriamycin (NSC-123,127): a new antibiotic with antitumor activity

1 reference

12 December 2020

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

1 reference

12 December 2020

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

1 reference

12 December 2020

A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer

1 reference

12 December 2020

A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin

1 reference

12 December 2020

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

1 reference

12 December 2020

Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin

1 reference

12 December 2020

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

12 December 2020

Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer

1 reference

12 December 2020

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes

1 reference

12 December 2020

1 reference

12 December 2020

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

12 December 2020

Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin.

1 reference

12 December 2020

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

1 reference

12 December 2020

Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity

1 reference

12 December 2020

A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL

1 reference

12 December 2020

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

12 December 2020

Paclitaxel and cisplatin in ovarian cancer

1 reference

12 December 2020

Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

1 reference

12 December 2020

A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas

1 reference

12 December 2020

Phase I and preliminary phase II evaluation of adriamycin (NSC 123127)

1 reference

12 December 2020

Lipid vesicles as carriers for introducing materials into cultured cells: influence of vesicle lipid composition on mechanism(s) of vesicle incorporation into cells

1 reference

12 December 2020

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

1 reference

12 December 2020

Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151)

1 reference

12 December 2020

Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group

1 reference

12 December 2020

Liposomal daunorubicin:in vitro andin vivo efficacy in multiple myeloma

1 reference

12 December 2020

Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice

1 reference

12 December 2020

Treatment of epidemic Kaposi's sarcoma with a combination of interferon-alpha 2b and etoposide

1 reference

12 December 2020

[Treatment of acute granulocytic leukemias by rubidomycin]

1 reference

12 December 2020

Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study

1 reference

12 December 2020

Caelyx in malignant mesothelioma: a phase II EORTC study

1 reference

12 December 2020

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

1 reference

12 December 2020

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1 reference

12 December 2020

Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

1 reference

12 December 2020

Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

1 reference

12 December 2020

10.1007/S11912-001-0016-5

Identifiers

DOI

1 reference

Dimensions Publication ID

5 July 2017

1005497039

0 references

1 reference